Month: November 2022

On May 31, 2020, O’Malley, Elissa; O’Brien, Jake W.; Verhagen, Rory; Mueller, Jochen F. published an article.Application In Synthesis of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate The title of the article was Annual release of selected UV filters via effluent from wastewater treatment plants in Australia. And the article contained the following:

We assessed the annual release of UV filters from wastewater treatment plant effluent in Australia and evaluated the removal of these chems. during wastewater treatment. Effluent samples were collected from 33 sites alongside matching influent samples. Sample collection predominately occurred during the Australian Census in August 2016, which allowed for accurate per capita normalization of the results. A subset of sites was also sampled over the Southern Hemisphere summer (Dec.-Feb.) period. Five UV filters were detected with at least one detected in 95% of effluent samples. The summed concentration of UV filters ranged from 130 ng L-1 to 8400 ng L-1 and averaged 2800 (±1900) ng L-1. Of the target UV filters, 2-phenylbenzimidazole-5-sulfonic acid (PBSA) and benzophenone 4 (BP4) showed the lowest removal efficiencies (11 ± 36% and 51 ± 43%, resp.) across all sites and were the most abundant in effluent. Average estimated removal efficiencies of the other compounds were between 59 (±24) % (4-methylbenzylidene camphor (4-MBC)) and 74 (±22) % (benzophenone 1 (BP1)). We did not find a trend in seasonal differences in the per capita release of UV filters in effluent samples. We estimate that approx. 40% of UV filter loads measured in influent are breaking through to the effluent resulting in the release of approx. 20 kg day-1 of the selected UV filters into the aquatic environment from treated wastewater effluent in Australia. The experimental process involved the reaction of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate(cas: 6197-30-4).Application In Synthesis of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate

The Article related to uv filter wastewater treatment plant effluent australia, australia, effluent, personal care products, sunscreen, uv filters, wastewater treatment, Waste Treatment and Disposal: Physical Treatment Of Aqueous Wastes and other aspects.Application In Synthesis of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 20, 2022, Fagervold, S. K.; Lebaron, P. published an article.Safety of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate The title of the article was Evaluation of the degradation capacity of WWTP sludge enrichment cultures towards several organic UV filters and the isolation of octocrylene-degrading microorganisms. And the article contained the following:

Organic UV filters are present in wastewater treatment plants (WWTPs) due to the use of these compounds in many personal care products (PCPs) and their subsequent release into the wastewater system from showering/bathing. Once in the wastewater system, organic UV filters generally partition into the solid phase but might also undergo other processes, such as degradation by microorganisms. To further understand the fate of organic UV filters in WWTPs, the degradation of 7 UV filters by WWTP sludge was investigated The UV filters 2-ethylhexyl salicylate (ES), homosalate (HS), Bu methoxydibenzoylmethane (BM) and octocrylene (OC) were degraded after 20-60 days. The rest of the filters tested, namely, bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT), methylene bis-benzotriazolyl tetramethylbutylphenol (MBBT) and diethylhexyl butamido triazone (DBT), did not degrade even after 120 days of incubation. The microbial community from the microcosms degrading ES, HS, OC and BM was transferred every 30 days into new microcosms to enrich for microorganisms capable of utilizing the individual UV filters for growth. The enrichment cultures continued to degrade throughout 20 transfers. The microbial community was clearly different between the enrichments degrading ES, HS, OC and BM, meaning that the microbial community was strongly influenced by the UV filter present. Furthermore, several strains were isolated from OC-degrading cultures and two of these strains, Gordonia sp. strain OC_S5 and Sphingopyxis sp. strain OC_4D, degraded OC with and without other carbon sources present. These experiments show that several organic UV filters can be degraded by a specific set of microorganisms. The lack of degradation observed for BEMT, MBBT and DBT is probably due to limited bioavailability. Indeed, this is the first biodegradation study of these filters, in addition to being the first description of ES and HS degradation in microcosm experiments The experimental process involved the reaction of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate(cas: 6197-30-4).Safety of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate

The Article related to octocrylene degrading microorganism wastewater treatment plant degradation capacity, degradation, pure bacterial strains, uv filters, wastewater sludge, Waste Treatment and Disposal: Physical Treatment Of Aqueous Wastes and other aspects.Safety of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 30, 1983, Naithani, Vinod K.; Schwertner, Eberhard published an article.Related Products of 53838-27-0 The title of the article was Human proinsulin VI. Synthesis of protected segment 46-70 of prohormone. And the article contained the following:

Title protected peptide Ph3C-Gly-Gly-Pro-Gly-Ala-Gly-Ser(CMe3)-Leu-Gln-Pro-Leu-Ala-Leu-Glu(OCMe3)-Gly-Ser(CMe3)-Leu-Gln-Lys(CO2CMe3)-Arg-Gly-Ile-Val-Glu(OCMe3)-Gln-OH was prepared by a series of fragment condensations in solution The final step involved 2 possible mixed anhydride condensations: the coupling of protected fragment 46-64 with protected fragment 65-70 or the coupling of protected fragment 46-59 with protected fragment 60-70. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Related Products of 53838-27-0

The Article related to proinsulin pentacosapeptide, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Related Products of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 26, 2016, Malolanarasimham, Krishnan; Murugan, Ravichandran Narayanasamy; Kedari, Chaitanya Kumar; Tulam, Vijaya Kumar published a patent.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Acylation process for the preparation of liraglutide. And the patent contained the following:

The invention is related to a process for the preparation of an N-substituted peptide or protein comprising: (a) reacting a peptide or protein with a copper agent to form a copper complex of peptide or protein; (b) converting the copper complex of the peptide or protein obtained in step (a) to the desired N-substituted peptide or protein in an organic solvent or in water or mixtures thereof; and (c) optionally, hydrolyzing the N-substituted peptide or protein obtained in step (b) to obtain the desired N-substituted peptide or protein, wherein the N-substituted peptide or protein is the GLP agonist H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6 -[N-(1-oxohexadecyl)-γ-Glu]-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH (liraglutide). The invention provides an alternate acylation process for preparation of liraglutide high yielding, scalable, cost effective, environment friendly and com. viable by avoiding repeated cumbersome and lengthy purification steps. Specifically, the invention is related to process for the preparation of liraglutide comprising: (i) reacting a liraglutide precursor with a copper agent, e.g., CuSO4•5H2O to form a copper complex of liraglutide precursor, (ii) converting the copper complex of liraglutide precursor obtained in step (i) to N-substituted liraglutide precursor by reacting with an N-acylating agent such as 1-Me palmityl glutamic acid or its reactive derivatives (preparation given); and (iii) hydrolyzing the N-substituted liraglutide precursor obtained in step (ii) to obtain liraglutide. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to acylation liraglutide preparation, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 11, 2017, Deng, Zeping; Chen, Fangjun published a patent.Formula: C9H8F2O2 The title of the patent was Preparation method of 2-(2,6-difluorobenzyl)pyrrolidine. And the patent contained the following:

The method relates to using 2-(2,6-difluorophenyl)acetic acid as initial material, carrying out esterification under action of catalyst, coupling in presence of alkali, opening loop with reducing agents, closing loop in presence of alkali, and reducing with reducing agent to obtain target product. The catalyst is one or more of 4-dimethylamino pyridine, p-Me Ph sulfonic acid, sulfuric acid, and/or thionyl chloride; the reducing agent is one or more of sodium borohydride, potassium borohydride, lithium borohydride, sodium cyano borohydride, lithium aluminum hydride, and/or borane. The compound is important medicine intermediate. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).Formula: C9H8F2O2

The Article related to difluorobenzylpyrrolidine preparation, Heterocyclic Compounds (One Hetero Atom): Pyrroles and Pyrrolizines and other aspects.Formula: C9H8F2O2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 31, 1985, Felix, Arthur M.; Heimer, Edgar P.; Wang, Ching Tso; Lambros, Theodore J.; Swistok, Joseph; Roszkowski, Martin; Ahmad, Mustaq; Confalone, Dianne; Scott, John W. published an article.Product Details of 53838-27-0 The title of the article was Synthesis of thymosin α1 by fragment condensation using tert-butyl side chain protection. And the article contained the following:

Thymosin α1 (I) was prepared by classical methods using 7 tert-Bu side chain protected fragments. Optimum conditions were found for the final DCC/HOBt coupling of the two key intermediates; decapeptide and octadecapeptide. I was purified by two stages of preparative HPLC (partial purification with C8 and final purification with C18 reverse phase silica gel) to give a 30% overall yield for the final four stages of synthesis (including catalytic hydrogenation of octadecapeptide, coupling, deprotection and purification). The product was homogeneous according to thin-layer and paper high voltage electrophoresis, isoelec. focusing anal., thin-layer chromatog. and high-performance liquid chromatog. Amino acid anal., optical rotation, 1H NMR spectroscopy, FAB mass spectroscopy and peptide mapping after tryptic digestion confirmed the structure of thymosin α1. Three minor stereoisomer contaminants were isolated by HPLC and characterized as [D-Lys14]-thymosin α1, [D-Lys17]-thymosin α1 and [D-Ala3]-thymosin α1 resulting from racemization at Lys14, Lys17 and Ala3 during the coupling of the fragments. A final contaminant, isolated by HPLC, was characterized as Nα-isobutyloxycarbonyl-thymosin α1 (15-28), which results from “wrong way opening” of an activated mixed anhydride. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Product Details of 53838-27-0

The Article related to thymosin synthesis fragment condensation, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Product Details of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Fagge, Ibrahim I.; Ahmad, W. Hamdah W.; Zain, Sharifuddin Md; Khan, M. Niyaz published an article in 2018, the title of the article was Kinetics and mechanism of counterionic salt-catalysed piperidinolysis of anionic phenyl salicylate in the presence of cationic-nonionic mixed micelles.Application In Synthesis of Phenyl Salicylate And the article contains the following content:

The quant. correlation of counterion-affinity to aqueous hexadecyltrimethylammonium bromide (HDAB, cationic micelles/nanoparticles) and the counterion-induced HDAB micellar growth, in the presence of different amounts of poly(ethylene glycol hexadecyl ether) (C16E20, nonionic surfactant), was achieved by the use of a semi-empirical kinetic (SEK) method. The values of the ratio of cationic HDAB, as well as mixed HDAB-C16E20, micellar binding constants of X and Br, KX/KBr (= KBrX or RBrX) for X = 4-ClC6H4CO2-, were obtained by the SEK method. The concentration range (0.006-0.015 M) of pure HDAB was found to have no influence on the values of KBrX or RBrX. These observations were also recorded upon addition of a nonionic surfactant, C16E20, in an aqueous solution of HDAB. The mean value of KBrX or RBrX obtained in the presence of pure HDAB (KBrX or RBrX = 50.3) is 2.3 times larger than that in the presence of mixed HDAB-C16E20 (mKBrX or mRBrX = 21.7). From rheometric measurements of aqueous HAD+/4-ClC6H4CO2- with 0.015 M HDAB, single sym. maxima (at both 25 and 35 °C) were obtained at [4-ClC6H4CO2Na] = 0.03 M. This is evidence for the existence of wormlike micelles/nanoparticles. However, the absence of a maximum in rheometric data for aqueous HAD+/C16E20/4-ClC6H4CO2- with 0.015 M HDAB and 0.006 M C16E20 at various [4-ClC6H4CO2Na] revealed the existence of spherical micelles. The experimental process involved the reaction of Phenyl Salicylate(cas: 118-55-8).Application In Synthesis of Phenyl Salicylate

The Article related to phenyl salicylate piperidinolysis kinetics, Physical Organic Chemistry: Other Reactions, Processes, and Spectra and other aspects.Application In Synthesis of Phenyl Salicylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 17, 1984, Meienhofer, Johannes A. published a patent.Application of 53838-27-0 The title of the patent was Immunopotentiating peptides. And the patent contained the following:

Peptides H-X-Glu-Asn-OH [X = null, Ala (I), Glu-Glu-Ala (II), Val-Glu-Glu-Ala, Val-Val-Glu-Glu-Ala] and their salts were prepared by known procedures. These di- to heptapeptides represent fragments of thymosin α1. Thus, I and II were prepared from their benzyl-protected derivatives by hydrogenolysis. I and II showed activity comparable to that of thymosin α1 in converting precursor T cells into steroid sensitive T1 cells or steroid resistant T2 cells. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Application of 53838-27-0

The Article related to immunopotentiation thymosin peptide fragment, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Application of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 14, 2006, Degrado, William F.; Bennett, Joel S.; Snyder, Seth Elliot; Choi, Sungwook published a patent.Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of prolyl dipeptides as inhibitors of the α2β1/gpIa-IIa integrin. And the patent contained the following:

The invention discloses novel compounds I [X is alkylidene; R1 is aralkylamino, aryl- or alkylsulfonylamino, carbalkoxymethyl, aralkoxycarbonylamino, NHSO2R2, where R2 is aryl, alkyl, aralkyl, aralkoxy, aralkylamino, arylamino, or alkylamino; R3 is halo, nitro, aryl, amino, alkyl, alkoxy, alkylsulfonyl, etc.; R4 is amino, hydroxy, aralkoxy, arylamino, aroylamino; R5 is H or alkyl; R6 is H or :O; A is SO2, PO2, CO2, CO; D is optional and may be one or more CH2 groups; E is aryl or heteroaryl; n, q are 0-2; m is 0 or 1; one of the three dashed-line portions may represent a double bond] or a stereoisomer, prodrug, pharmaceutically-acceptable salt, or N-oxide, which inhibit the integrin α2β1/GPIa-IIa receptor and are useful for the treatment of α2β1-affected disease states. Thus, prolyl peptide II was prepared and showed IC50 = 15 nM for inhibition of platelet adhesion to type I collagen. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to prolyl peptide preparation inhibitor integrin, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 4, 2012, Degrado, William F.; Bennett, Joel S.; Snyder, Seth Elliott; Choi, Sungwook published a patent.Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Inhibitors of the α2β1/gpia-iia integrin. And the patent contained the following:

Novel compounds inhibiting the integrin α2β1/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use. The compounds disclosed are useful, inter alia, as inhibitors of integrin α2β1/GPIa-IIa-mediated activity. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to prolyl peptide preparation inhibitor integrin, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics